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Abstract
The density of circulating hepatitis C virus (HCV) particles in the blood of chronically infected patients is very
heterogeneous. The very low density of some particles has been attributed to an association of the virus with
apolipoprotein B (apoB) positive and triglyceride rich lipoproteins (TRL) likely resulting in hybrid lipoproteins known as lipo-
viro-particles (LVP) containing the viral envelope glycoproteins E1 and E2, capsid and viral RNA. The specific infectivity of
these particles has been shown to be higher than the infectivity of particles of higher density. The nature of the association
of HCV particles with lipoproteins remains elusive and the role of apolipoproteins in the synthesis and assembly of the viral
particles is unknown. The human intestinal Caco-2 cell line differentiates in vitro into polarized and apoB secreting cells
during asymmetric culture on porous filters. By using this cell culture system, cells stably expressing E1 and E2 secreted the
glycoproteins into the basal culture medium after one week of differentiation concomitantly with TRL secretion. Secreted
glycoproteins were only detected in apoB containing density fractions. The E1–E2 and apoB containing particles were
unique complexes bearing the envelope glycoproteins at their surface since apoB could be co-immunoprecipitated with E2-
specific antibodies. Envelope protein secretion was reduced by inhibiting the lipidation of apoB with an inhibitor of the
microsomal triglyceride transfer protein. HCV glycoproteins were similarly secreted in association with TRL from the human
liver cell line HepG2 but not by Huh-7 and Huh-7.5 hepatoma cells that proved deficient for lipoprotein assembly. These
data indicate that HCV envelope glycoproteins have the intrinsic capacity to utilize apoB synthesis and lipoprotein assembly
machinery even in the absence of the other HCV proteins. A model for LVP assembly is proposed.
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Introduction
Hepatitis C virus (HCV) infects an estimated 3% of the world
population and frequently causes chronic infection often leading to
cirrhosis and liver cancer. The virus was first isolated in 1989 by
molecular biology techniques [1] and classified in the Hepacivirus
genus within the Flaviviridae family, which includes the flaviviruses
(e.g. yellow fever virus and Dengue virus), the pestiviruses (e.g.,
bovine viral diarrhoea virus), and GB viruses [2]. However, the
high frequency of chronic infections and the very narrow host
range limited to humans and chimpanzees sets HCV apart from
the other flaviviruses. Since its discovery, many aspects of the
HCV replication cycle as well as the pathophysiology of chronic
hepatitis C have been described (for recent reviews, see [3,4]).
Surprisingly, despite the possibility to propagate the virus in vitro,
the precise nature of the HCV particle is still poorly understood in
contrast to the flaviviruses that have been studied in great details
[5–7]. Unique to HCV is the exceptional low density of the virus
particles resulting from the association of the virus with
lipoproteins [8,9]. Low density complexes of HCV and lipopro-
teins are preferably observed in the blood of chronically infected
patients while most of the viral particles produced in vitro have a
density similar to that of flaviviruses [10,11].
The density of the blood circulating forms of HCV is very
heterogeneous ranging from 1.25 to less than 1.06 g/mL. Particles
with high density could correspond to naked capsids [12]. Particles
in plasma density fraction around 1.15 g/mL may represent
conventional viruses similar to those produced in Huh-7 cells that
are derived from the highly replication competent JFH1 strain
(HCVcc) [13–15]. Viral particles in density fractions below
1.06 g/mL are associated with apolipoprotein B (apoB) bearing
triglyceride rich lipoproteins (TRL), namely the low, intermediate
and very low density lipoproteins (LDL, IDL and VLDL,
respectively) and chylomicrons [9,10,16–19]. This uncommon
association of a virus with lipoproteins is of particular interest since
viral particles of low density have a higher specific infectivity than
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Huh-7 cell culture system [11,20,21]. A transmission case of
hepatitis C suggests that low density viral particles are also
infectious in humans [22]. It is not clear however, whether every
circulating HCV particles are associated with apoB, the triglyc-
eride content of the particle being the parameter changing the
density, or whether only the low density particles are apoB positive
and triglyceride rich viral complexes.
Because of their association with TRL, the low density particles
have been assigned the name of lipo-viro-particles (LVP) [10]. The
proportion of LVP amongst the circulating viral particles varies
from patient to patient, but on average almost half of HCV RNA
is detected in the circulating plasma fractions with density lower
than 1.06 g/mL. LVPs are recognized by host antibodies and
these immunoglobulin positive particles can be purified by protein
A precipitation. Electron microscopy studies identified purified
LVPs as globular particles that are heterogeneous in size with an
average diameter of 100 nm. These contain higher amounts of
triglycerides than lipoproteins isolated from the same density
fractions and they contain apolipoproteins (B, CII, CIII, and E,
but not the HDL-associated apoA) as well as the viral RNA, core
protein and envelope glycoproteins E1 and E2 [10,18]. Treatment
of LVP with detergent does not destroy the association of HCV
RNA with apoB [18]. Surprisingly, the two apoB isoforms, apoB
100 and apoB 48, are present in LVP with comparatively more
apoB 48 in LVP than in the plasma [16]. While apoB 100 is
produced by the liver, apoB 48 is only synthesized by enterocytes
and is essential for the formation of chylomicrons [23]. This is in
keeping with the existence of an intestinal site of HCV assembly
and maturation that is supported by the detection of viral non
structural proteins in enterocytes of chronically infected patients
and the change in neutral lipid composition of LVP content early
after a fat rich meal [16,24].
The nature of LVP however remains poorly defined and the
process leading to the coassembly of lipoproteins and virus hybrid
complexes is not understood. It has been suggested that LVP
formation occurs at the ER membrane where TRL synthesis takes
place [25] since HCV RNA can already be immunoprecipitated by
anti-apoB antibodies in chronically infected liver macerates [26]. In
support to this hypothesis, it was recently shown that in vitro
production of HCV in the Huh-7 cellline depends on the assembly of
VLDL and on the expression of apoE [27–29]. It has also been
documented that HCV envelope glycoproteins E1 and E2 are
retained in the endoplasmic reticulum (ER) by retention signals in
their transmembrane domains (for review see [30,31]). Concerning
LVP, E1 and E2 appear to be exposed on the surface of purified LVP
since they can be recognized by anti-envelope antibodies under non
denaturating conditions [16]. The envelope glycoproteins may thus
play a pivotal role in the formation of LVP. To better understand the
interaction between envelope glycoproteins and TRL and the
assembly of LVP, E1 and E2 proteins were stably expressed in cell
lines secreting apoB positive lipoproteins. It is shown here that the
viral glycoproteins are secreted from these cells only when the TRL
synthesis and secretion pathway is functional. Moreover, the resulting
hybrid TRL particles bear E1 and E2 glycoproteins at their surface.
These findings reveal that HCV envelope glycoproteins have the
intrinsic capacity to assemble into TRL.
Results
Establishment and characterization of Caco-2 cells
expressing HCV envelope glycoproteins
The human intestinal cell line Caco-2 does not synthesize apoB
and MTP when cultured under standard conditions and therefore
does not secrete apoB-containing lipoproteins. Caco-2 cells
maintained under these conditions were infected with the E1E2-
HIV-SIN lentiviral vector. After transduction, E1 and E2 proteins
with the expected molecular weight could be detected in cell
lysates by Western blotting (Figure 1A). Immunofluorescence
analysis indicated that almost all cells expressed the glycoproteins
(Figure 1B) and that the expression was stable for at least 40
passages. However, when cultured on porous filter allowing
asymmetrical culture conditions with serum free medium in the
upper chamber and complete medium in the lower chamber of the
culture device, Caco-2 cells partially differentiate into polarized
cells and regain the capacity to synthesize and secrete TRL at their
basal membrane into the lower chamber a few days after cells
reach confluence (Figure 2A) [32,33].
As shown in the time course experiment in Figure 2B and in
agreement with previous reports [32,33], apoB could only be
detected in the basal compartment of the culture 7 days after cell
seeding. Concentrations of apoB then increased until day 13.
Interestingly, in E1E2 expressing cells, the apoB secretion was
significantly delayed but still reached a similar high level at day 13.
Although E2 was always detected in cell lysates (Figure 2C), a
fraction of E2 was detected in the basal medium concomitant with
the apoB secretion, suggesting that HCV envelope proteins are
secreted with apoB. Cell differentiation was also correlated with an
increased amount of intracellular E2 (Figure 2C).
HCV glycoproteins are not secreted by the apoB negative
epithelial Hela cell line
The secretion of HCV glycoproteins was only detected
concomitantly with the synthesis and secretion of apoB positive
lipoproteins by E1E2-Caco-2 cells suggesting that a functional
apoB pathway is necessary for E1E2 secretion. We then tested if
the two glycoproteins could nevertheless be also secreted by
epithelial cell line not from hepatic or intestine origin and not
producing lipoproteins. Hela cells were transduced by the E1E2
lentiviral vector and were found, as Caco-2 cells, to stably express
the glycoproteins as shown by immunostaining (Figure 3A). By
contrast, the glycoproteins were not detected in the supernatant of
E1E2-Hela cells as they were in E1E2-Caco-2 basal medium
(Figure 3B).
Characterization of the apoB and HCV envelope
glycoprotein complexes
To further investigate the association of glycoproteins and TRL,
E1E2 expressing and control Caco-2 cells were cultured under
differentiation conditions and the basal medium collected at day
13 was analyzed in an iodixanol density gradient. Figure 4 shows
that the glycoprotein E2 and isoforms of apoB and apoE were
detected in fractions with the lowest density (#1.05 g/mL) with
the maximum concentration in the 1.035 g/mL fraction. Con-
cerning apoB, the two isoforms, apoB100 and apoB48, were
secreted in comparable molar concentrations. This further
confirms the differentiation state of the cells that can edit, at least
partially, the apoB mRNA to synthetize apoB48 [32]. The
distribution of the two glycoproteins E1 and E2 in a highly
resolved density gradient is shown in Figure 5. Both glycoproteins
co-sedimented in apoB containing fractions from E1E2-Caco-2
cells but not in corresponding fractions from control Caco-2 cells
(Figure 5 A and B). Interestingly, although apoB was still present in
fractions with the lowest density of about 1.02 g/mL, the two
glycoproteins and particularly E1 were confined to the apoB
positive fractions with a density from 1.07 to 1.05 g/mL
suggesting that different lipoproteins were secreted into the basal
Secretion of HCV Glycoproteins
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associated with the glycoproteins and the group of hybrid
lipoproteins which had a higher density presumably because of
the additional viral proteins. E1 was mainly detected as monomer
(apparent MW of ,30 kD) in the fractions with the highest density
(fraction 16 and 17) and not in the other fractions where E2 was
also detected. Some additional bands with molecular weight of
70 kD that may correspond to E1 trimers [34] were also detected
in the other E2 positive fractions (data not shown). However, these
high molecular weight bands co-migrated with a non specific cross
reacting protein present in apoB positive fractions leaving open the
question of the existence of E1 trimers associated with apoB
particles of lower density. Alternatively, the weakest reactivity of
anti-E1 antibody on western blot than the anti-E2 antibody
reactivity might limit the detection of E1. Finally both glycopro-
teins might not be secreted with the same efficiency.
To confirm that both glycoproteins are associated with
lipoproteins, complexes from unfractionnated basal medium were
immuno-precipitated using an E2-specific conformational mono-
clonal antibody. Only immuno-precipitated complexes from
E1E2-Caco-2 cells but not from control cell basal medium
(Figure 5C) contained E1 and the two isoforms of apoB in
addition to E2. Taken together these data indicate that E1 and E2
glycoproteins can be integrated into at least some TRL that are
secreted at the basolateral side of differentiated epithelial cells and
that they are present on the surface of the lipoprotein complexes.
HepG2 but not Huh-7 cell lines secretes HCV
glycoproteins as hybrid TRL
To extend the results found with intestinal cells to liver cells, and
as HCV predominantly replicates in the liver, the viral
glycoproteins were expressed by transduction with the lentiviral
particles in the human hepatic cell line HepG2, often used as a
model for TRL secretion. As observed with the Caco-2 model, E1
and E2 secreted in the supernatant were only found in low density
fractions with apoB (Figure 6B). Similarly to the Caco-2 model, the
E1E2-HepG2 cells secreted the glycoproteins as hybrid apoB
positive particles, which could be immuno-precipitated with the
E2-specific monoclonal antibody (Figure 6C). However, as
expected, apoB was only found as the apoB100 isoform since
human liver cells cannot edit the apoB mRNA.
When testing E1E2-Huh-7.5 cells that support HCVcc
replication, we also found that E1 and E2 were secreted into
low density fractions of the supernatant (Figure 7B) indicating that
these proteins were associated with lipids. But in strong contrast
with the Caco-2 and HepG2 models and despite many attempts, if
it was still possible to co-immunoprecipitate E1 with E2-specific
antibody, it was not possible to co-immunoprecipitate apoB and,
in the best cases as shown on Figure 8C, only traces of apoB, and
not much more than from control cell supernatant, could be
detected on these E1 and E2 positive low density complexes. We
obtained the same lack of association of envelope glycoproteins
and apoB with a parental Huh-7 cell line (data not shown). These
data suggest that in Huh-7 cell lines, apoB positive lipoproteins
and lipid associated envelope glycoproteins could likely not fuse in
single hybrid particles.
Inhibition of MTP decreases apoB and viral glycoproteins
secretion
MTP (microsomal triglyceride transfer protein) is an essential
protein in the synthesis and assembly of TRL in both the liver and
intestine. To evaluate the role of MTP in the synthesis and
Figure 1. Expression of the HCV glycoproteins E1 and E2 in Caco-2 cells. Caco-2 cells maintained under standard culture conditions after
transduction with the E1E2-HIV-SIN lentiviral vector express E1 and E2 proteins. (A) Western blot analysis showing E1 and E2 revealed as single bands
by anti-E1 antibody, (lane 2), and anti-E2 antibody (lane 4), at their expected molecular weight in transduced cells, but not in control cells (lanes 1 and
3, respectively). (B) Expression of envelope glycoprotein remains stable. Staining of transduced cells with anti-E2 antibody (in red) shows that almost
all cells still expressed the envelope protein after at least 40 passages.
doi:10.1371/journal.pone.0004233.g001
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were grown under conditions of differentiation for 11 days before
the MTP inhibitor Cp 346086 was added [35]. MTP activity and
the secretion of apoB and E2 were measured one and two days
later. As shown in Figure 8A, MTP activity was inhibited in a dose
dependant manner by 35 and 50% at one or two days after
addition of the inhibitor, respectively. ApoB secretion was reduced
in parallel in similar proportions (Figure 8B) while the secretion of
MIP-1 beta in the basal medium was not affected suggesting that
the MTP inhibitor specifically reduced the apoB lipoprotein
secretion but not the secretion of unrelated proteins (data not
shown). Most importantly if the intracellular expression of the two
glycoproteins was not modified by the MTP inhibition, the
quantity of E1 and E2 secreted into the basal medium after 24 h
or 48 h incubation with 1 and 10 nM inhibitor, was greatly
reduced and correlated with the concentration of secreted apoB
(Figure 8C).
The effect of MTP inhibition on the two glycoproteins secretion
by E1E2-HepG2 cells was very similar to that observed with
E1E2-Caco-2 cells (Figure 9A) with around 40% reduction of E2
secretion and 30% reduction of E1 secretion after 48 h in presence
of 1 nM inhibitor. The same effect was also observed with E1E2-
Huh-7.5 cells (Figure 9B) but to a lower extent with only 16% and
8% reduction of respectively E2 and E1 secretion in the same
inhibitor conditions. The effect of MTP inhibition on the two
glycoproteins secretion seemed also to depend on the lipoprotein
pathway since the secretion of albumin by these two liver derived
cell lines was not modified (data not shown).
Discussion
In both Caco-2 and HepG2 cell culture systems, the HCV
glycoproteins are secreted with the apoB positive lipoproteins. This
secretion is strictly dependent on an efficient apoB positive
lipoprotein secretion pathway because, first, apoB negative
epithelial Hela cells do not secrete HCV envelope proteins, second,
Caco-2 cells only secrete the viral glycoproteins after having
acquired the apoB synthesis and secretion capacity and, finally,
inhibition of a normal lipidation of apoB with an MTP inhibitor
reduced the amount of the secreted viral glycoproteins. The E1 and
E2 envelope proteins thus containthe signals mandatory to interfere
with a functional apoB pathway in liver and intestinal cells. It is
worth noting that both systems seem to be interdependent. Indeed,
the amount of cellular viral glycoproteins increases accordingly to
apoB and conversely the presence of E1 and E2 likely delays the
secretion of apoB. A metabolic syndrome frequently associated with
hepatitis C includes insulin-resistance, liver steatosis and hypo-beta-
lipoproteinemia. Decreased serum apoB concentrations have been
attributed to inhibition of MTP activity by HCV core protein
[36,37] and by the facilitated degradation of apoB by the non
structural protein NS5A [38] which both could reduce the
production of TRL. Here we found that expression of E1 and E2
delaysapoB secretionbyCaco-2cellsprovidinganothermechanism
for reduced apoB serum concentration.
Transduction of the gene coding for E1 and E2 without any
additional viral genes is sufficient to induce the assembly and the
secretion of low density hybrid particles resembling TRL and
Figure 2. Kinetic of ApoB and HCV glycoprotein secretion during Caco-2 cell differentiation. (A) Caco-2 cells were grown on porous
filters under asymmetric medium conditions as depicted for two weeks after seeding. Media in upper and lower chambers were changed every two
days. Under these differentiation conditions, basolateral lipoprotein secretion begins after one week of culture [32]. (B) ApoB secreted by control and
E1E2 transduced cells into the basal medium was measured by ELISA. Values indicate apoB (ng) secreted by one thousand cells for two days per mL
of culture medium. Vertical bars indicate standard deviations. The kinetic is representative of three separate experiments. (C) Expression and secretion
of E2 protein by E1E2-Caco-2 cells during differentiation. Content of E2 protein in 40 ml of basal medium, upper pannel, and, in cell lysate, lower
panel, (per 20 mg total protein), was analysed every two days by Western blotting with the E2-specific H52 antibody. As indicated in Figure 1, E2 was
detectable in seeded cells and remained present during the two weeks of culture. Its expression increased during the early phase of the
differentiation until day 9 when a plateau was reached. E2 secretion into the basal medium began at day 7, concomitantly with apoB secretion.
Secreted E2 appeared to have a higher molecular weight than the control intracellular E2 protein likely because of a higher glycosylated state.
doi:10.1371/journal.pone.0004233.g002
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VLDL or chylomicron assembly model is envisioned as a two steps
process which requires at least apoB and MTP (for reviews see
[39–41] and Figure 10). During the first step, apoB is synthesized
and translocated into the rough ER lumen forming a lipid binding
cavity that is completed with MTP. MTP thus allows the
recruitment of phospholipids and triglycerides (step 2). The
ongoing translation of apoB concomitant with MTP mediated
lipid transfer from the ER lipid droplets forms a neutral lipid core
and conversion to a spherical emulsion particle (step 3). After
release from the ribosome, the apoB precursors (precursor 1) move
to a distal compartment in the secretory pathway (step 4) where
they meet with apoB-free luminal lipid droplets or second
precursor, formed by MTP in the smooth ER (step 5–6). The
first and second precursors fuse to form mature TRL, a process
that may be facilitated by apoE, another major component of
TRL [42,43]. In that model, it seems unlikely that a transfer of the
viral glycoproteins from the ER membrane where they reside to
the apoB precursor may occur. Indeed such a leap would need
energy and/or complex tertiary or quaternary rearrangement of
the glycoproteins induced by an hypothetical binding to the
nascent precursor and allowing the transmembrane domain to
detach from the ER membrane. The formation of the apoB free
precursor is less well understood (step 5–6). If it also depends on
MTP, the mechanism leading to a luminal lipid droplet limited by
a monolayer of phospholipids is not known. It is tempting to
hypothesize that E1 and E2 may slide from the ER membrane to
the budding apoB free precursor without any energetically costly
conformational changes. In Caco-2 and HepG2 cells, the envelope
proteins associated with the second precursor would then fuse with
the apoB precursors to form mature hybrid particles. On the
contrary, in Huh-7, the fusion likely does not occur and envelope
proteins are secreted associated with lipids, and likely with the
second precursors, a process that seems to depend on MTP since
the secretion of both glycoproteins could be reduced by an MTP
inhibitor but less efficiently than in Caco-2 and HepG2 cells. E1
and E2 might therefore be envisioned as markers of the second
precursor supporting the two precursor model of lipoprotein
synthesis.
These data support the recently published hypothesis that some
viral particles could result from co-assembly of viral particles and
lipoproteins [25] and at least partially explain why apoB and/or
MTP inhibition reduces the production of infectious viral particles
in Huh-7 cells [28,29]. Chang and colleagues in addition showed
that ApoE is required for the production of infectious virus in cell
culture [27]. As apoE is involved directly or indirectly in the
second precursor formation [43], the reduction of intracellular and
secreted virions by apoE knockdown could result from the
suppression of the second VLDL precursor assembly. Altogether,
these data indicate that both steps of VLDL formation and
Figure 3. Epithelial Hela cells do not secrete HCV glycoproteins. (A) Analysis of HCV glycoprotein expression by E1E2-Hela by
immunofluorescence with E2-specific antibody H52. Cells were grown under standard conditions and stained as described in materials and methods.
Left panel, control cells, right panel, E1E2-Hela. E2 positive cells are stained in red. (B) Caco-2 and E1E2-Caco-2 cells were cultured under
differentiating conditions for 11 days followed by 2 days in FCS free medium before baso-lateral medium and cells were collected. Hela and E1E2-Hela
cells were cultured in standard conditions until 80% confluence and then kept for two days in FCS free medium before cells and supernatants were
collected. Cellular and medium samples for western blotting were adjusted for the total cellular protein contents. HCV glycoproteins were detected in
both E1E2-Caco-2 and E1E2-Hela cell and not in control cells (left panel) but the two glycoproteins were only secreted by E1E2-Caco-2 and not by
E1E2-Hela and control cells (right panel).
doi:10.1371/journal.pone.0004233.g003
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that secreted virions are associated with apoB while other particles
are degraded [28]. Interestingly however the latter data were
obtained in Huh-7 that is shown here to be defective for proper
assembly of VLDL with a defect either in the second precursor
formation or in the two precursor fusion step since apoB and
glycoproteins are present on separate low density molecular
complexes. Virions produced in Huh-7 might benefit from the
second precursor to assemble and to be associated with lipid in an
MTP dependent manner, but could only marginally fused with the
apoB precursor leading to particles with some density heteroge-
neity that cannot be immunoprecipitated by anti-apoB antibody
[29]. The pathways for biosynthesis of TRL triglyceride both in
liver and intestine involve several key enzymes [44,45] which may
not be fully functional in Huh-7.
In our experimental system, the formation of the hybrid
lipoproteins only required the presence of the envelope glycopro-
teins. Conversely, the formation of infectious virions may benefit
from the budding of the hybrid precursor. Recently, it was
proposed that HCV core localizes on the monolayer membrane of
cytosolic lipid droplets and then recruits replication complexes
associated with the ER membrane forming a membranous local
environment critical for producing infectious viruses [46,47]. It is
thus tempting to speculate that, in this local environment,
assembling capsids might profit of the budding hybrid second
precursor driven by the envelope glycoproteins and MTP to
translocate within the precursor lipid core to form an uncompleted
viral particle. That particle could secondly fuse in competent cells
with the first precursor in the presence of apoE forming the lipo-
viro-particles. Translocation of the nucleocapsid limited by the
core hydrophobic domains into the lipid core may be energetically
favored by the phospholipid monolayer surrounding the hybrid
precursor.It is likely that many defective particles circulate in the
blood of chronically infected patients since particles containing
only E1 and E2 can be produced in large amount as observed in
this system. Previous LVP studies reported that purified LVP
contained more apoB than HCV RNA molecules suggesting that
some hybrid particles recognized by endogenous antibody are
defective viral particles [10,16].
This study shows that viral envelope proteins interfere with the
apolipoprotein B pathway to be secreted and provides further
evidences on the nature and on the assembly of LVP. Hepatitis C
virus also appears as a valuable tool for studying the successive
steps of VLDL and chylomicron synthesis and secretion.
Figure 4. Density and nature of apolipoproteins and HCV glycoproteins secreted into Caco-2 basal medium. E1E2-Caco-2 cells were
grown on porous filters under asymmetric medium conditions for 11 days. Upper and lower culture medium were then changed and replaced with
foetal calf serum free medium. Cells were incubated for two additional days. Basal medium was collected and run on an iodixanol gradient. (A)
Density fractions were collected and apoB concentrations per mL of basal medium were determined by ELISA and expressed in ng/ml. ApoB was only
present in fractions with density #1.05 g/mL. (B) Density fractions were analysed by western blotting using specific antibodies against apoB, apoE
and E2 glycoprotein. ApoB positive fractions contained the two apoB isoforms, apoB100 and apoB48. ApoE and E2 were only detected in the apoB
positive fractions. Control proteins were deposited in lane +.
doi:10.1371/journal.pone.0004233.g004
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Materials
Unless indicated, all chemicals were from Sigma. Monoclonal
antibodies anti-E1 (clone A4) or E2 (clones H52 and H48) mAbs
were obtained from Dr J. Dubuisson (Institut de Biologie de Lille-
Institut Pasteur de Lille, France). Anti-apoB (clone 1D1) mAb was
from the Heart Institute (University of Ottawa, Ontario, Canada),
anti-apoB (clone 1609) monoclonal antibodies and peroxidase-
conjugated goat anti-apoB antibodies were from Biodesign (Saco,
ME, USA). Anti-apoE (clone 3D12) was obtained from Millipore
(Molsheim, France). The MTP inhibitor CP346086 [35] was
kindly provided by G. Luo (Department of Microbiology,Univer-
sity of Kentucky College of Medicine, Lexington, Kentucky). Cell
culture reagents were obtained from Invitrogen (Cergy-Pontoise,
France) and FCS (foetal calf serum) from PAN-Biotech GmbH
(Aidenbach, Germany). Microporous polyethylene terephthalate
membrane inserts were from Becton Dickinson (Le Pont de Claix,
France) (4.2 or 0.3 cm
2,1mm pore size).
Lentiviral particles production and cell transduction
A lentiviral vector E1E2-HIV-SIN for the transduction of the
HCV glycoproteins E1 and E2 was constructed. The gene coding
the E1 and E2 from HCV genotype 1a H77 strain (AJ 318514,
nucleotides 733 to 2579) were introduced at the Bsrg I and BamHI
restriction sites of the HIV-1 self-inactivating vector backbone
pRRL-SIN18-cPPT-hPGK-EGFP-WPRE (pHIV-hPGK-GFPW+,
[48]) under the control of the internal human phosphoglycerate
kinase (hPGK) promoter. Retrovirus carrying the E1E2-HIV-SIN
sequence was produced by co-transfection of the Gag pol packaging
construct pCMVdeltaR8.91 [49] and glycoprotein expression
construct pCMV-VSV-G (AJ 318514) in 293T cells (ATCC
CRL-1573).
2.4610
6 293T cells per 55 cm
2 culture dish (Corning) were
seeded 24 h prior to transfection in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 2 mM glutamine, 100 i.u./
ml penicillin, 100 mg/ml streptomycin and 10% heat-inactivated
FCS in a 95% humidified incubator containing 5% CO2 in air at
37uC. For the production of E1E2-HIV particles, 13.2 mgo f
Figure 5. Characterization of the apoB and envelope containing particles secreted into Caco-2 basal medium. Cells were cultured as in
Figure 4. Basal medium was collected at day 13 after two day incubation in serum free medium. Density of apoB and E1E2 glycoprotein positive
fractions in the E1E2-Caco-2 basal medium. Basal medium was run on a iodixanol gradient and fractions were analysed by apoB Elisa (A) and western
blotting (B, upper panel) stained with envelope specific H52 and A4 antibodies. E1 and E2 proteins were present in apoB positive fractions with the
higher density leaving the upper apoB fractions free of envelope glycoproteins. E1 was only detected in the fractions with the highest density.
Intracellular E1 and E2 control proteins were deposited in the last right lane (+). To further assess the specificity of the antibody, fractions obtained
from E1E2-Caco-2 and control Caco-2 grown in the same conditions were normalized for apoB concentrations and ran in parallel in one western blot
(B, lower panel). Envelope glycoproteins were only detected in fractions obtained from E1E2-Caco-2. (C) Immuno-precipitation of E2 positive particles.
Basal culture medium of control Caco-2 and E1E2-Caco-2 cells were collected at day 13 of differentiation after two days of culture in serum free
medium. E2 positive particles were captured by E2-specific H48 monoclonal antibody and immuno-precipitated particles were analysed by western
blotting and stained with anti-E2 H52 (upper panel), anti-E1 A4 (middle panel) and anti-apoB (lower panel) antibodies as described in materials and
methods section. Molecular weights are indicated on the left, control proteins were deposited in the + lane. Identical volume of precipitated material
either from E1E2-Caco-2 or control Caco-2 basal medium were deposited in lanes ‘‘E1E2’’ and ‘‘control’’ respectively for every western blot.
doi:10.1371/journal.pone.0004233.g005
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packaging plasmid and 13.2 mg of E1E2-HIV-SIN derived vector
plasmid were co-transfected by calcium phosphate precipitation.
Medium was replaced with 0.1 ml/cm
2 of fresh culture medium
without serum 14–16 h post-transfection.Viral supernatants were
harvested 24 h later, cleared by low-speed centrifugation, and
filtered through a 0.45 mm low binding protein filter (Millex filter
unit, Millipore) prior to concentration. High-titer viral stocks were
prepared by concentrating viral supernatants about 100 fold
through ultracentrifugation for 2 h in a Beckman LE 70
ultracentrifuge at 26 000 rpm at 4uC in an SW28 rotor. Viral
stocks were aliquoted in PBS 1% glycerol and stored at 280uC.
7 ng of p24 antigen (HIV P24 II Vidas, Vidas apparatus,
BioMe ´rieux) with 8 mg/ml polybrene in culture medium was
used to infect overnight target cells, plated at 100 000 in a 2 cm
2
well the day before.
Cell culture
Caco-2 cells (ATCC HTB-37) were plated on inserts at a
density of 250 000 cells /4.2 cm
2 transwell and grown until
confluency (,6 days post seeding) in DMEM (Dulbecco’s modified
Eagle’s medium) containing 25 mM glucose and 2 mM glutamine,
supplemented with penicillin (100 i.u./ml) and streptomycin
(100 mg/ml), 1% non-essential amino acids and 20%(v/v) heat-
inactivated FCS. Cells were then cultured for an additional week
under asymmetrical conditions with media containing FCS in the
lower compartment and media without FCS in the upper
compartment. Media were changed every 48 hours. For incuba-
tions with MTP inhibitor CP346086, fresh medium without FCS
was added to the lower and upper compartment at the final
concentrations of inhibitor for 24 or 48 hours. HepG2 (ATCC
HB-8065), Huh-7.5 (from Charles Rice, Rockefeller University,
New York, New York), Huh-7 cells (from John Mac Lauchlan,
MRC, Glasgow, UK), and Hela (ATCC CCL-2) were plated in
9.5 cm
2 wells at a density of 400 000 cells/well and grown for
24 h or 48 hours (until 80% confluence) in DMEM containing
25 mM glucose and 2 mM glutamine, supplemented with
penicillin (100 i.u./ml), streptomycin (100 mg/ml), 1% non-
essential amino acids and 10% (v/v) heat-inactivated FCS before
the following experiments. For experiments with the MTP
inhibitor CP346086, fresh medium without FCS was added to
the 9.5 cm
2 wells containing 0, 1 or 10 nM inhibitor for 48 hours.
Figure 6. Characterization of particles secreted by HepG2. (A) Analysis of HCV glycoprotein expression by immunofluorescence with E2-
specific antibody H52. HepG2 cells were grown under standard conditions and stained as described in materials and methods. Left panel, control
cells, right panel, E1E2 transduced HepG2 cells. E2 positive cells are stained in red. (B) Density of apoB and E1E2 positive fractions in the E1E2-HepG2
supernatant. Three day culture supernatant was run on an iodixanol gradient and fractions were analysed by apoB ELISA, upper panel, and western
blotting with E2-specific antibody, lower panel. Envelope control proteins were deposited in the last right lane (+). E2 proteins were only present in
apoB positive fractions. (C) Immuno-precipitation of E2 positive particles was performed as in figure 5 with HepG2 supernatant collected three days
after seeding. Basal culture medium of control and E1E2-HepG2 were collected after two days of culture in serum free medium. E2 positive particles
were captured by E2-specific H48 monoclonal antibody and immuno-precipitated particles were analysed by western blotting and stained with E2-
specific H52 antibody (upper panel), E1-specific A4 antibody (middle panel) and apoB-specific antibody (lower panel). Molecular weight are indicated
on the left, control proteins were deposited in the + lane.
doi:10.1371/journal.pone.0004233.g006
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Cells were fixed with formaldehyde 4% in PBS (formaldehyde
37%, Merck) for 30 minutes at 4uC and permeabilized by triton
X100 0.5% in PBS for 30 minutes at 4uC. Intracellular expression
of HCV E2 protein was assayed by indirect immunofluorescence
with anti-E2 H52 antibody (10 mg/ml) and Alexa Fluor 546
F(ab’)2 fragment of goat anti-mouse immunoglobulin G (1 mg/ml,
Invitrogen). Cells were countercolored with Hoechst 33 342
(0,2 mg/ml) and observed with a Leica DMIRB microscope.
ApoB ELISA
ApoB concentrations in the medium of the lower compartment
were determined by ELISA. Ninety-six-well flat-bottomed ELISA
plates (Maxisorb; Nunc) were coated overnight at 4uC with 100 ml
monoclonal anti-human apoB antibody (5 mg/ml; clone 1609) in
PBS and then saturated with 2% BSA for 1 h. Samples were
distributed at 100 ml per well. After 2 h incubation at 37uC and
washing with PBS/ 0,05% Tween 20, 100 ml of peroxidase-
conjugated goat anti-human apoB antibody (1.6 mg/ml) 100 ml
per well in PBS/ 0.2% BSA were added for 90 min at 37uC. The
plates were washed and o-phenylenediamine substrate was added
(100 ml per well). The reaction was revealed for 30 min and
absorbance was read at 450 nm. Standard curves were established
with apoB dilutions ranging from 10 to 200 ng/ml apoB (ApoB
kit, SFRI Diagnostics).
To normalized quantity of apoB produced by 1000 cells, the
number of viable cells in 0.3 cm
2 transwells was determined by
CellTiter 96H AQueous Non-Radioactive Cell Proliferation Assay
(Promega). The MTS conversion into formazan was realized into
transwells according to manufacturer recommandations. The
absorbance at 490 nm of formazan product in transwells
supernatants was measured after transfer to a 96-well plate.
Iodixanol density gradients
Iodixanol gradients were prepared as described by Nielsen et al.
[18]. Isopycnic linear density gradients were prepared from 6%
(wt/vol) (1.7 ml of 60% [wt/vol] iodixanol, 0.34 ml of 0.5 M Tris-
HCl, pH 8.0, 0.34 ml of 0.1 M EDTA, pH 8.0, and 14.6 ml
Figure 7. Characterization of particles secreted by Huh-7.5 cells. (A) Analysis of HCV glycoprotein expression by immunofluorescence with
E2-specific antibody. Huh-7.5 were grown under standard conditions and stained as described in materials and methods. Left panel, control cells,
right panel, E1E2 transduced Huh-7. E2 positive cells are stained in red. (B) Density of apoB and E1E2 positive fractions in the E1E2-Huh-7.5
supernatant. Three day culture supernatant was run on a iodixanol gradient and fractions were analysed by apoB ELISA, upper panel, and western
blotting with E1 and E2-specific antibodies, lower panel. Envelope control proteins were deposited in the last right lane (+). E1 and E2 proteins were
only present in apoB positive fractions. (C) Immuno-precipitation of E2 positive particles was performed as in figure 5 with Huh-7.5 supernatant
collected three days after seeding. Basal culture medium of control and E1E2-Huh-7.5 were collected after two days of culture in serum free medium.
E2 positive particles were captured by E2-specific H48 monoclonal antibody and immuno-precipitated particles were analysed by western blotting
and stained with H52 anti-E2 (upper panel), A4 anti-E1 (middle panel) and anti-apoB (lower panel) antibodies. Molecular weight are indicated on the
left, control proteins were deposited in the + lane.
doi:10.1371/journal.pone.0004233.g007
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0.34 ml of 0.5 M Tris-HCl, pH 8.0, 0.34 ml of 0.1 M EDTA,
pH 8.0, and 0.34 ml 0.25 M sucrose) iodixanol solutions in
thinwall centrifuge tubes (14689 mm, Beckman) using a two-
chamber gradient maker. A sample of 1 ml lower compartment
medium was applied to the top of 6 to 56% iodixanol gradients
and centrifuged for 10 h in a Beckman Optima L100 XP
ultracentrifuge at 41000 rpm and 4uC in an SW41 rotor. The
gradient was harvested by tube puncture from the bottom and
collected into 11 (1 ml each) or 22 fractions (0.5 ml each). The
density of each fraction was determined by measuring the mass of
100 mL.
Co-immunoprecipitation
Co-immunoprecipitations were performed with mMACS Protein
G Magnetic MicroBeads according to the manufacturer’s instruc-
tions (Miltenyi Biotec, Bergisch Gladbach, Germany). 0.2 mgo f
anti-E2 H48 was added to 2 ml of the lower compartment medium
before overnight incubation at 4uC. After one hour incubation with
20 ml of protein G microbeads, labelled immune-complexes were
applied into a mMACS MS column. After one wash with PBS/BSA
0.2%, the retained immunoprecipitate was eluted in 100 ml of pre-
heated (95uC) gel loading buffer.
Western blot
Samples preparation: Media or gradient fractions were collected
in Laemmli buffer and immediately frozen at 220uC until
analysis. Cell layers were briefly rinsed twice with ice-cold PBS
(Invitrogen), scraped into 0.5 ml of lysis buffer (1% Triton X-100
and 5 mM EDTA in PBS) supplemented with 2% (v/v) protease
inhibitor cocktail (P8340; Sigma–Aldrich), and immediately frozen
at 220uC. Cell lysates were run through a small bore needle (25G
5/80) a few times. The protein concentration was determined
using the Micro BCA Protein Assay (Perbio Science) with BSA as
standard protein and samples were then diluted in loading buffer
prior to fractionation by SDS-PAGE. Positive controls for
ApoB100 and ApoB48 were obtained from purified human
lipoproteins as follows. Plasma sample from a postprandial healthy
Figure 8. MTP activity inhibition decreases HCV envelope glycoprotein secretion by E1E2-Caco-2. E1E2-Caco-2 cells were cultured under
differentiating condition for 11 days when medium was replaced by FCS free medium with the MTP inhibitor Cp 346084 at 0, 1 or 10 nM. MTP activity
was measured on frozen lysates and expressed as described in the Materials and Methods section. (A) MTP activity in lysate of E1E2-Caco-2, 24 and
48 h after addition of Cp 346084. MTP activity was not completely abrogated by the addition of the inhibitor since its activity continued to increase
during the inhibition period. However, there was a dose dependant inhibition of MTP activity by 1 and 10 nM Cp 346084. (B) Concentrations of
secreted ApoB in the basal medium were measured by ELISA at 24 and 48 h after addition of 1 or 10 nM Cp 346084. ApoB secretion was inhibited in a
dose dependant manner by the MTP inhibitor. (C) Secretion of HCV glycoprotein E1 and E2 in the basal medium was monitored by western-blotting
with the E1-specific A4 and E2-specific H52 antibodies at 24 and 48 h after addition of 1 or 10 nM Cp 346084. Control cellular E2 protein was
deposited in lanes (+). Amount of secreted E1 and E2 was quantified by densitometry as per cent of secreted glycoprotein in absence of inhibitor
(upper panels). Cellular glycoprotein expression was monitored by western-blotting of cell lysates and was not modified by MTP inhibition (lower
panel).
doi:10.1371/journal.pone.0004233.g008
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ultracentrifuge (Beckman instruments). Upper low-density fraction
was collected and 100-fold diluted in Laemmli buffer before
denaturation. Positive controls for E1 and E2 were obtained from
a lysate of cells expressing HCV glycoproteins.
20 mg of cell protein lysates, 40 ml of gradient fraction or 20 ml
of immunoprecipitate were heated for 5 minutes at 95uC,
fractionated by SDS-PAGE and transferred to a PVDF mem-
brane. After an overnight incubation at 4uC in PBS-0.1% Tween
20 supplemented with 5% (w/v) non-fat milk powder, blots were
probed with mAb against apoB, E1 or E2 diluted in PBS-0.1%
Tween 20 (1:5000 for apoB, 1:1000 for E1 and E2 ) for 90 minutes
followed by a peroxidase-conjugated goat anti-mouse antibody
(Perbio Science; 1:5000 dilution for 1 h in the same buffer). Blots
were developed with enhanced chemiluminescence reagents
according to the manufacturer’s instructions (SuperSignal West
Femto Maximum Sensitivity Substrate , Perbio Science).
MTP Activity
MTP activity was measured with the Research Assay Kit for
MTP (Chylos Inc.) according to manufacturer instructions with
minor modifications. Briefly, for kinetic study, cells in inserts
were washed with ice-cold PBS, dryed and frozen at day 7, 9,
11 and 13, and stored at 220uC until MTP activity assay. Cells
from a 4.2 cm
2 insert were homogenized into 150 mlo f5 0m M
tris-HCl, pH 7.4, 50 mM KCl and 5 mM EDTA homogeniza-
tion buffer. Cell lysates were run through a small bore needle
(25G 5/80) twenty times. The assay was done in white
microplates (Nunc GmbH, Wiesbaden, Germany). To the wells,
we added 10 ml of cell homogenate, 5 ml of substrate vesicles
mix and distilled water to make a final volume of 100 ml.
Microplates were incubated at 37uC for 2 h before fluorescence
reading using 460 nm excitation and 530 nm emission wave-
lengths into a Wallac 1420 Victor2
TM microplate Fluorimeter
(PerkinElmer, Courtaboeuf, France). To determine background
fluorescence value, vesicles fluorescence was measured in
absence of cell lysate after 2 h incubation in the same
conditions. Background value was then subtracted from each
sample. Protein concentrations in cell homogenates were
determined using a Bradford protein assay kit (Sigma-Aldrich)
and results were expressed as units of fluorescence per mgo f
protein.
Figure 9. MTP activity inhibition decreases HCV envelope glycoprotein secretion by E1E2-HepG2 and E1E2-Huh-7.5. E1E2-HepG2 and
E1E2-Huh-7.5 cells were cultured in standard conditions until 80% confluence when medium was replaced by FCS free medium with 0, 1 or 10 nM of
MTP inhibitor Cp 346084 for two days. MTP activity was measured on frozen lysates and expressed as described in the Materials and Methods section.
(A) E1E2-HepG2 and (B) E1E2-Huh-7.5. Upper panels, MTP activity in cells and apoB concentrations in medium in presence of the indicated inhibitor
concentrations. Middle panels, quantification of secreted glycoproteins in presence of 1 and 10 nM MTP inhibitor by western blotting and
densitometry as per cent of secreted glycoproteins in absence of inhibitor. Lower panels, cellular glycoprotein expression was not modified by the
MTP inhibitor as shown by western-blotting of cell lysates.
doi:10.1371/journal.pone.0004233.g009
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